Global Nexus Network

.With a solid track record for pinpointing diamonds in the rough, Bain Funds Life Sciences (BCLS) has actually come to be a highly effective interject

.Welcome to today’s Chutes &amp Ladders, our roundup of notable leadership hirings, firings and also retirings throughout the sector. Satisfy deliver the praise– or the

.Bristol Myers Squibb is axing yet another large wager from the Caforio time, canceling a package for Agenus’ TIGIT bispecific antibody three years after spending

.Bristol Myers Squibb is paying Excellent Medication $110 million in advance to develop reagents for ex-spouse vivo T-cell therapies. Excellent, which can receive an immense

.Bristol Myers Squibb has had a whiplash change of heart on its own BCMA bispecific T-cell engager, halting (PDF) additional progression months after submitting to

.AvenCell Rehabs has safeguarded $112 thousand in collection B funds as the Novo Holdings-backed biotech looks for clinical proof that it may generate CAR-T tissues

.Atea Pharmaceuticals’ antiviral has failed another COVID-19 trial, however the biotech still keeps out really hope the prospect has a future in hepatitis C.The oral

.Pinetree Rehabs are going to assist AstraZeneca vegetation some trees in its pipe along with a new deal to build a preclinical EGFR degrader worth

.AstraZeneca has settled CSPC Pharmaceutical Group $one hundred million for a preclinical cardiovascular disease drug. The deal, which covers a possible competitor to an Eli

.AstraZeneca has discussed an early take a look at the efficiency of its own in-house antibody-drug conjugate (ADC) technology, posting period 1 data on candidates